| Effect | Increase |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 20 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Average |
Supplementation of N-acetylcysteine at 600mg once daily for ten weeks in persons with stable COPD has resulted in less Eosinophil cationic protein (ECP; indicative of granulocyte breakdown) and less adhesion factors, which are thought to underlie the mucolytic properties and sputum reduction.
